<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5915</td>
<td>Highlights of This Issue</td>
<td></td>
</tr>
<tr>
<td>5917</td>
<td><strong>CCR Translations</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Braking Bad: Blockade of Inhibitory Pathways Improves Interleukin-15 Therapy</td>
<td>William E. Carson III</td>
</tr>
<tr>
<td>5920</td>
<td>Toward a Better Understanding of Race and Cancer</td>
<td>Otis W. Brawley</td>
</tr>
<tr>
<td>5923</td>
<td><strong>CCR Drug Updates</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pazopanib in Renal Cell Carcinoma</td>
<td>James E. Ward and Walter M. Stadler</td>
</tr>
<tr>
<td>5928</td>
<td><strong>Molecular Pathways</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hypoxia and Hypoxia-Inducible Factors: Master Regulators of Metastasis</td>
<td>Xin Lu and Yibin Kang</td>
</tr>
<tr>
<td>5936</td>
<td>Targeting RET Receptor Tyrosine Kinase Activation in Cancer</td>
<td>John E. Phay and Manisha H. Shah</td>
</tr>
<tr>
<td>5942</td>
<td><strong>Review</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Resveratrol: Challenges in Translation to the Clinic — A Critical Discussion</td>
<td>Lalita Subramanian, Sherry Youssef, Saswati Bhattacharya, Jason Kenealey, Arthur S. Polans and Paul R. van Ginkel</td>
</tr>
<tr>
<td>5950</td>
<td><strong>CCR Focus</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Striving to Improve Outcomes in Oncology: Unmet Expectations in a Complex Disease</td>
<td>Susan E. Bates</td>
</tr>
<tr>
<td>5951</td>
<td>Translating Clinical Trials into Meaningful Outcomes</td>
<td>Patricia M. LoRusso, Lowell E. Schnipper, David J. Stewart, Scott A. Boerner, Steven D. Averbuch and Walter Wolf</td>
</tr>
<tr>
<td>5956</td>
<td>Making the Investigational Oncology Pipeline More Efficient and Effective: Are We Headed In the Right Direction?</td>
<td>Patricia M. LoRusso, Aparna B. Anderson, Scott A. Boerner and Steven D. Averbuch</td>
</tr>
<tr>
<td>5963</td>
<td>Evaluating Patient-Centered Outcomes in the Randomized Controlled Trial and Beyond: Informing the Future with Lessons from the Past</td>
<td>Christopher M. Booth</td>
</tr>
<tr>
<td>5972</td>
<td>Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much?</td>
<td>Tito Fojo and David R. Parkinson</td>
</tr>
<tr>
<td>5981</td>
<td>Explaining Marginal Benefits to Patients, When “Marginal” Means Additional but Not Necessarily Small</td>
<td>Thomas J. Smith and Bruce E. Hillner</td>
</tr>
<tr>
<td>5997</td>
<td>The Impact of Insurance on Access to Cancer Clinical Trials at a Comprehensive Cancer Center</td>
<td>Justin F. Klamerus, Suanna S. Bruinooge, Xiaobu Ye, Mandi L. Klamerus, Dorothy Damron, Dina Lansey, John C. Lowey, Luis A. Diaz Jr., Jean G. Ford, Norma Kanarek and Charles M. Rudin</td>
</tr>
<tr>
<td>6004</td>
<td>Value and Cancer Care: Toward an Equitable Future</td>
<td>Lowell E. Schnipper, Neal J. Meropol and Dan W. Brock</td>
</tr>
</tbody>
</table>
HUMAN CANCER BIOLOGY

6009  IQGAP1 Plays an Important Role in the Invasiveness of Thyroid Cancer
Zhi Liu, Dingxie Liu, Ermal Bojdani, Adel K. El-Naggar, Vasily Vasko and Mingzhao Xing

IMAGING, DIAGNOSIS, PROGNOSIS

6083  Genotypic Profiling of 452 Choroidal Melanomas with Multiplex Ligation-Dependent Probe Amplification
Bertil Damato, Justyna A. Dopierala, Sarah E. Coupland

6093  Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer
Gustavo S.P. Meirelles, Heiko Schöder, Gregory C. Ravizzini, Mitthat Gonen, Josef J. Fox, John Hiumm, Michael J. Morris, Howard I. Scher and Steven M. Larson

CANCER THERAPY: PRECLINICAL

6019  Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model
Ping Yu, Jason C. Steel, Melli Zhang, John C. Morris and Thomas A. Waldmann

6029  Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma
Saadia A. Aziz, Lucia B. Jilaveanu, Christopher Zito, Robert L. Camp, David L. Rimm, Patricia Conrad and Harriet M. Kluger

6040  The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations

6049  Microenvironmental Regulation of Glioblastoma Radioresistance
Muhammad Jamal, Barbara H. Rath, Eli S. Williams, Kevin Camphausen and Philip J. Tofton

6060  The Notch Target Hes1 Directly Modulates Gli1 Expression and Hedgehog Signaling: A Potential Mechanism of Therapeutic Resistance
Karisa C. Schreck, Pete Taylor, Luigi Marchionni, Vidya Gopalakrishnan, Eli E. Bar, Nicholas Gaiano and Charles G. Eberhart

6071  A Hypoxia- and α-Fetoprotein–Dependent Oncolytic Adenovirus Exhibits Specific Killing of Hepatocellular Carcinomas
Oh-Joon Kwon, Pyung-Hwan Kim, Steven Huyn, Lily Wu, Minjung Kim and Chae-Ok Yun

CANCER THERAPY: CLINICAL

6122  CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
Mark E. Dudley, Colin A. Gross, Michelle M. Langhan, Marcos R. Garcia, Richard M. Sherry, James C. Yang, Giao Q. Phan, Udai S. Kammula, Marybeth S. Hughes, Deborah E. Citrin, Nicholas P. Restifo, John R. Wunderlich, Peter A. Prieto, Jenny J. Hong, Russell C. Langan, Daniel A. Zlott, Kathleen E. Morton, Donald E. White, Carolyn M. Laurencot and Steven A. Rosenberg

6132  Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAh-009 in Patients with Mesothelin-Expressing Cancers
Raffit Hassan, Steven J. Cohen, Martin Phillips, Ira Pastan, Elad Sharon, Ronan J. Kelly, Charles Schweizer, Susan Weil and Daniel Laheru
Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine

Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study
Denis C. Talbot, Malcolm Ranson, Joanna Davies, Michael Lahn, Sophie Callies, Valérie André, Sunil Kadam, Michael Burgess, Christopher Slapak, Anna L. Olsen, Peter J. McGh, Johann S. de Bono, Julian Matthews, Azeem Saleem and Patricia Price

A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Monika Graeser, Afshin McCarthy, Christopher J. Lord, Kay Savage, Margaret Hills, Janine Salmon, Nicholas Orr, Marina Parton, Ian E. Smith, Jorge S. Reis-Filho, Mitch Dowsett, Alan Ashworth and Nicholas Turner,

Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer
Song Yao, William E. Barlow, Kathy S. Albain, Ji-yeob Choi, Hua Zhao, Robert B. Livingston, Warren Davis, James M. Rae, Ji-tien Yeh, Laura F. Hutchins, Peter M. Radvan, Silvana Martino, Alan P. Lyss, C. Kent Osborne, Martin Abeloff, Gabriel N. Hortobagyi, Daniel F. Hayes and Christine B. Ambrosone

Chromosome 17 Polysomy without HER2 Amplification Does Not Predict Response to Lapatinib in Metastatic Breast Cancer—Letter
Cathy B. Moelans, Roel A. de Weger and Paul J. van Diest

Chromosome 17 Polysomy without HER2 Amplification Does Not Predict Response to Lapatinib in Metastatic Breast Cancer—Response
Leona Downey and Robert Livingston

Do Rectal Cancer Patients with PIK3CA Mutations Benefit from Preoperative Radiotherapy with Regard to Local Recurrences?
Youji He, Laura J. Van’t Veer, Marta Lopez-Yurda, Cornelis J.H. van de Velde and Corrie A.M. Marijnen

Clinical Usefulness of Microarrays for Cancer Prognosis in 2010—Letter
Serge Koscielny and Stefan Michiels

Statistical Evaluation of Clinical Usefulness of Microarrays for Cancer Prognosis Needs to be Placed in the Context of Clinical Reality—Response
Weida Tong and Xiaohui Fan

Acknowledgment to Reviewers
ABOUT THE COVER

Intracerebral xenograft initiated from the CD133⁺ glioblastoma stem-like cell line GBM1. At the initial signs of morbidity (94 days after implantation) a representative mouse was euthanized and the brain tumor prepared for histological analyses. This figure shows the immunofluorescent analyses of GFAP (red) and III tubulin (green) with nuclei counterstained with DAPI (blue) at 20x magnification. For details, see the article by Jamal and colleagues on page 6049 of this issue.
Clinical Cancer Research

16 (24)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/16/24

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.